AstraZeneca Could Seek New Indication For Iressa In Europe

The company announces withdrawal of European Marketing Authorisation Application for gefitinib in treatment of non-small cell lung cancer. FDA is expected to provide an update on the status of Iressa's subpart H approval in January or February.